Last $56.12 USD
Change Today -0.24 / -0.43%
Volume 348.0K
Q On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

quintiles transnational hold (Q) Snapshot

Open
$56.60
Previous Close
$56.36
Day High
$56.73
Day Low
$55.85
52 Week High
08/18/14 - $57.65
52 Week Low
10/31/13 - $40.10
Market Cap
7.1B
Average Volume 10 Days
375.0K
EPS TTM
$2.48
Shares Outstanding
127.3M
EX-Date
--
P/E TM
22.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for QUINTILES TRANSNATIONAL HOLD (Q)

quintiles transnational hold (Q) Related Businessweek News

No Related Businessweek News Found

quintiles transnational hold (Q) Details

Quintiles Transnational Holdings Inc., through its subsidiary, Quintiles Transnational Corp., provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through two segments, Product Development and Integrated Healthcare Services. The Product Development segment provides project management and clinical monitoring services, including study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, and project management for conducting various multi-site trials; and clinical trial support services comprising clinical data management, biostatistical, central laboratories, genomic laboratory, bioanalytical laboratories, cardiac safety and ECG, safety and pharmacovigilance, and phase I clinical pharmacology services. It also provides strategic planning and design services; and consulting services, such as product development strategy, regulatory and compliance, and process and IT implementation consulting services. The Integrated Healthcare Services segment offers commercial services comprising contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, and medical education services; communication and health engagement services, including digital patient, and brand and scientific communications services; and outcome-based services, such as observational studies, comparative effectiveness studies, and product and disease registry services. The company serves biopharmaceutical companies, including medical device and diagnostics companies. Quintiles Transnational Holdings Inc. was founded in 1982 and is based in Durham, North Carolina.

30,700 Employees
Last Reported Date: 07/31/14
Founded in 1982

quintiles transnational hold (Q) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.0M
Executive Chairman
Total Annual Compensation: $871.2K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.1M
Chief Customer & Governance Officer and Execu...
Total Annual Compensation: $838.4K
Consultant
Total Annual Compensation: $526.3K
Compensation as of Fiscal Year 2013.

quintiles transnational hold (Q) Key Developments

Quintiles Transnational Holdings Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of 2014

Quintiles Transnational Holdings Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $1,341,030,000 compared to $1,295,680,000 a year ago. Income from operations was $141,000,000 compared to $94,897,000 a year ago. Net income was $85,110,000 compared to $38,353,000 a year ago. Net income attributable to the company was $85,120,000 compared to $38,517,000 a year ago. Diluted earnings per share were $0.64 compared to $0.30 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $114,139,000 compared to $46,719,000 a year ago. Adjusted EBITDA was $171,793,000 compared to $149,080,000 a year ago. Adjusted income from operations was $141,948,000 compared to $124,094,000 a year ago. Adjusted net income was $85,722,000 compared to $62,925,000 a year ago. Diluted adjusted earnings per share were $0.65 compared to $0.50 a year ago. For the six months, the company reported total revenues of $2,648,876,000 compared to $2,524,521,000 a year ago. Income from operations was $282,316,000 compared to $210,062,000 a year ago. Net income was $175,324,000 compared to $86,509,000 a year ago. Net income attributable to the company was $175,303,000 compared to $86,826,000 a year ago. Diluted earnings per share were $1.32 compared to $0.71 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $236,851,000 compared to $128,676,000 a year ago. Net cash provided by operating activities was $38,697,000 compared to $1,385,000 a year ago. Acquisition of property, equipment and software was $35,832,000 compared to $60,277,000 a year ago. Adjusted EBITDA was $343,205,000 compared to $292,078,000 a year ago. Adjusted income from operations was $284,272,000 compared to $242,452,000 a year ago. Adjusted net income was $176,666,000 compared to $120,545,000 a year ago. Diluted adjusted earnings per share were $1.33 compared to $0.98 a year ago. The company provided earnings guidance for the full year of 2014. For the period, the company increased service revenue guidance to $4.20 billion to $4.24 billion and increased diluted adjusted EPS guidance to $2.57 to $2.67 per share, representing diluted adjusted EPS growth of 22.4% to 27.1% compared to full year 2013. The annual effective income tax rate is estimated to be approximately 30%. This financial guidance is based on the actual results for the first six month period of 2014 combined with the estimates for the following six months of 2014, assuming the June foreign currency exchange rates stay in effect for the remainder of the year, and does not reflect the impact of any future equity repurchases. Diluted GAAP earnings per share expected to be between $2.49 and $2.61 per share.

Basilea Pharmaceutica AG Enters into Agreement with Quintiles for the Commercialization of Zevtera(R)/Mabelio(R) in Europe

Basilea Pharmaceutica AG reported that it has entered into an agreement with Quintiles for the commercialization of Zevtera(R)/Mabelio(R) (ceftobiprole medocaril) in Europe. Under the agreement, Quintiles will provide commercial services including a dedicated field force, medical science liaisons, and market access support in selected countries.

Quintiles Transnational Holdings Inc. to Report Q2, 2014 Results on Jul 31, 2014

Quintiles Transnational Holdings Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
Q:US $56.12 USD -0.24

Q Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioanalytical Systems Inc $2.20 USD +0.01
View Industry Companies
 

Industry Analysis

Q

Industry Average

Valuation Q Industry Range
Price/Earnings 23.7x
Price/Sales 1.8x
Price/Book NM Not Meaningful
Price/Cash Flow 22.7x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUINTILES TRANSNATIONAL HOLD, please visit www.quintiles.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.